Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


SAGE Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

July 10, 2017
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 12, 2017
Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression

June 8, 2017
Sage Therapeutics to Present at Goldman Sachs Healthcare Conference

Read More News

Associated Team Members

Kevin Starr
Partner